Healthesystems is attending the IRSG Conference, which is designed for leaders in the insurance, medical, and rehabilitation fields.
Visit Healthesystems in booth #1833 as we exhibit at RISKWORLD, a conference for risk management professionals.
Approval Date: Oct 2023
Indicated for the treatment of moderate to severe ulcerative colitis
Approval Date: Oct 2023
Indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and other autoimmune conditions, this drug is now available in an intravenous formulation
Approval Date: Oct 2023
Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Approval Date: Oct 2023
Indicated for the short term management of mild to moderate acute pain, and the management of moderate to severe pain as an adjunct to opioid analgesics, this drug is now available in an intravenous formulation
Approval Date: Sep 2023
Indicated for the treatment of rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs)
Approval Date: Sep 2023
Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis
Approval Date: Sep 2023
Indicated for the treatment of major depressive disorder (MDD), a first-in-class drug that selectively targets the serotonin 1A receptor
Approval Date: Aug 2023
Indicated for the topical treatment of plaque psoriasis
Approval Date: Jul 2023
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Approval Date: Jul 2023
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate
